Skip to main content
Luoxin Pharmaceuticals Group Stock Co., Ltd. logo

Luoxin Pharmaceuticals Group Stock Co., Ltd. — Investor Relations & Filings

Ticker · 002793 ISIN · CNE1000026S7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,601 across all filing types
Latest filing 2026-01-13 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002793

About Luoxin Pharmaceuticals Group Stock Co., Ltd.

https://www.luoxin.cn

Luoxin Pharmaceuticals Group Stock Co., Ltd. focuses on the research, development, manufacturing, and distribution of diverse medicinal products. The company specializes in therapeutic areas including digestive health, respiratory medicine, anti-infectives, and oncology. Its portfolio includes various formulations such as injections, tablets, and capsules, with a notable emphasis on proton pump inhibitors and respiratory treatments. Luoxin operates a vertically integrated model, producing both active pharmaceutical ingredients (APIs) and finished dosage forms. The organization emphasizes innovation through dedicated R&D facilities to develop high-quality healthcare solutions. Its operations are supported by a comprehensive supply chain and manufacturing infrastructure designed to adhere to international quality standards, serving broad market segments with a focus on clinical efficacy and patient accessibility.

Recent filings

Filing Released Lang Actions
独立董事提名人声明与承诺（许霞）
Board/Management Information Classification · 95% confidence The document is a formal statement and commitment by a nominator regarding the nomination of an independent director candidate for the company's board. It details qualifications, compliance with laws and regulations, and declarations of independence and suitability for the role. There are no financial statements, earnings data, or report attachments. The content is focused on board/management information, specifically about director nomination and related compliance. The document length is 3225 characters, which is relatively short and consistent with a nomination statement rather than a full report. Therefore, the document fits best under the category of Board/Management Information (MANG).
2026-01-13 Chinese
关于董事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Luoxin Pharmaceutical Group Co., Ltd. regarding the re-election of the board of directors. It details the nomination and qualifications of candidates for the sixth board, including both independent and non-independent directors. The content focuses on board member changes, their qualifications, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The document is clearly about changes in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is over 5,000 characters and contains detailed information about board members, not just a brief announcement or report publication notice.
2026-01-13 Chinese
董事、高级管理人员离职管理制度
Board/Management Information Classification · 95% confidence The document is titled as a management system for the resignation of directors and senior management personnel of the company. It details procedures, responsibilities, and legal compliance related to the departure of board members and executives. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, no capital changes, and no regulatory filings or announcements. The content is focused on internal governance policies related to board and senior management personnel changes. Therefore, the document fits best under the category of Board/Management Information (MANG), which covers announcements or information about changes in the company's board or senior management.
2026-01-13 Chinese
公司章程修改条款对比表
Governance Information Classification · 95% confidence The document is a detailed comparison table of amendments to the company's articles of association (章程修改条款对比表). It includes changes to governance structures, shareholder meeting procedures, director duties, profit distribution policies, and other corporate governance matters. The content focuses on internal rules, board and shareholder meeting procedures, director qualifications and responsibilities, and profit distribution policies, which are typical elements of corporate governance documentation. There is no indication of financial statements, audit opinions, earnings data, or other financial report content. The document is not an announcement of a report but the actual text of governance-related amendments. Therefore, the document best fits the category of Governance Information (CGR).
2026-01-13 Chinese
公司章程
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association for 罗欣药业集团股份有限公司 (Luoxin Pharmaceuticals Group Stock Co., Ltd.). It includes chapters on company general provisions, business scope, shares, shareholders and shareholders' meetings, board of directors, senior management, financial accounting system, profit distribution, audit, labor management, notices and announcements, mergers, amendments to the charter, and other corporate governance matters. It references Chinese company law, securities law, and regulatory approvals from the China Securities Regulatory Commission (CSRC). The content is focused on the company's internal governance rules, shareholder rights, board structure, and operational procedures rather than financial results or announcements. It is not an annual report, earnings release, call transcript, or any other financial or market disclosure. It is a governance document detailing the company's internal rules and governance practices. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is the full governance document, not just an announcement or summary.
2026-01-13 Chinese
授权管理制度
Governance Information Classification · 95% confidence The document is titled '授权管理制度' which translates to 'Authorization Management System' for 罗欣药业集团股份有限公司. It outlines the company's internal authorization management rules, decision-making authority, and governance procedures related to company operations, board and shareholder meeting powers, and transaction approval thresholds. There is no financial data, no mention of financial results, no earnings, no audit opinions, no voting results, no legal proceedings, no capital changes, and no investor presentation content. The document is a governance-related internal policy document describing the company's internal rules and governance practices. Therefore, it fits best under the category 'Governance Information' (CGR). The document length is 2897 characters, which is not a brief announcement but a substantive governance policy document. Hence, the classification is CGR with high confidence.
2026-01-13 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.